Emerging risk factors for stroke. What have we learned from Mendelian randomization studies? by Hopewell, J, Clarke, R

Radiobiological compensation for unintended treatment interruptions during palliative radiotherapy. by Jones, B, Hopewell, J, Dale, R

The role of lipoprotein(a) in chronic kidney disease by Hopewell, J, Haynes, R, Baigent, C

Impact of inflammatory interleukin-1 genotypes on risk of infection in UK Biobank by Camm, C, Casadei, B, Hopewell, J

Pharmacogenomics of statin therapy: any new insights in efficacy or safety? by Hopewell, J, Reith, C, Armitage, J

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study by Hopewell, J, Parish, S, Armitage, J, Collins, R

Response to 'position statement on ethics, equipoise and research on charged particle therapy' by Jones, B, Howick, J, Hopewell, J, Liew, S

Response to 'Position statement on ethics, equipoise and research on charged particle therapy'. by Jones, B, Howick, J, Hopewell, J, Liew, S

Identifying systematic heterogeneity patterns in genetic association meta-analysis studies by Magosi, L, Goel, A, Hopewell, J, Farrall, M

The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease by Hopewell, J, Stari, T, Parish, S, Collins, R, Clarke, R, Consortium, METASTROKE

Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes by Rothwell, P, Hopewell, J, Li, L, Lindgren, C, Morris, A

Mendelian randomization with fine‐mapped genetic data: choosing from large numbers of correlated instrumental variables by Burgess, S, Zuber, V, Valdez-Marquez, E, Sun, B, Hopewell, J

Independent Relevance of Cytokines for Risk of Coronary Heart Disease by Clarke, R, Hopewell, J, Hill, M, Farrall, M, Watkins, H

Fractionation effects in particle radiotherapy: implications for hypo-fractionation regimes. by Carabe-Fernandez, A, Dale, R, Hopewell, J, Jones, B, Paganetti, H

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study by Hopewell, J, Clarke, R, Parish, S, Armitage, J, Collins, R, Study, HP

Oxidized phospholipids, Lp(a) and coronary heart disease risk by Clarke, R, Hopewell, J, Tsimikas, S, Watkins, H, Farrall, M, Consortium, PROCARDIS

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study by Hopewell, J, Parish, S, Clarke, R, Armitage, J, Collins, R, Collaborati, H

Changes in the retreatment radiation tolerance of the spinal cord with time after the initial treatment by Woolley, T, Belmonte-Beitia, J, Calvo, G, Hopewell, J, Gaffney, E, Jones, B

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. by Hopewell, J, Clarke, R, Parish, S, Armitage, J, Lathrop, M, Hager, J, Collins, R

Effects of variations in overall treatment time on the clonogenic survival of V79-4 cells: Implications for radiosurgery by Hallgren, S, Hill, M, Thompson, J, Elliott, A, Paddick, I, Jones, B, Hopewell, J